9.00am - 5.00pm EST | 6.00am - 2.00pm PST
8:30 am Registration & Coffee
Spotlights Beyond CD47 Targeting to Expand Macrophage Therapy Repertoire
9:25 am Chair’s Opening Remarks
9:30 am Industry Leader’s Fireside Chat: A Roundup of Clinical Development with a Focus on Clinical Validation
Synopsis
• Unraveling clinical success stories to reaffirm the potential of macrophage-directed therapies and boost
investment in the macrophage space
• Addressing key dosing, safety, and efficacy challenges to accelerate clinical results
10:30 am Exosome Mediated Genetic Reprogramming of Tumor-Associated Macrophages
Synopsis
• Engineered exosomes allow selective targeting of undruggable transcription factors in macrophages
• exoASO-STAT6 induces reprogramming of tumor-associated macrophages and promotes CD8 T-cell mediated adaptive immune responses
• exoASO-STAT6 shows potent monotherapy activity in several mouse syngeneic models
11:00 am
Morning Refreshments & Speed Networking
11:01 am
Preclinical & Discovery
Determining Optimal Combination Therapies to Enhance Efficacy
12:00 pm Profile of BYON4228, a Selective Pan-Allelic SIRPα Blocking Antibody Designed to Improve Efficacy of Therapeutic Anti-Tumor Antibodies
Synopsis
• BYON4228 potentiates both macrophage- and neutrophil-mediated elimination of hematologic and
solid cancer cells in vitro in the presence of several different tumor-targeting antibodies.
• BYON4228 does not recognize the closely related T-cell expressed SIRPα.
• BYON4228 is well tolerated by cynomolgus monkeys. Clinical studies are planned to start in 2022
12:30 pm The Potency of Macrophage Repolarization as a Monotherapy Approach Versus the Need to Combine with Other Treatments
Synopsis
• Macrophage repolarization sets in motion many arms of the anti-tumor response
• Mechanistic combination potential
• Is successful monotherapy possible, and where would it be most effective?
Clinical & Translational
Exploring Clinical Developments Outside CD47 Targeting
12:00 pm Employing a CAR-Macrophage Approach to Successfully Tackle Solid Tumors
Synopsis
• Preclinical background for the development of Carisma Therapeutics CT-0508
• Clinical development of CAR-macrophage therapy with Carisma Therapeutics CT-0508
• Next steps for the development of Carisma Therapeutics CAR-macrophage therapeutic development
12:30 pm Development of Eganelisib, a First-in-Class PI3Kgamma Inhibitor for Next Generation Macrophage Reprogramming Cancer Immunotherapy
Synopsis
• Discovery of Eganelisib and characterization of MOA
• Summary of Eganelisib clinical development program with a focus on translational data
1:00 pm
Lunch Break & Networking
Utilizing Macrophage Interactions to Enrich Targeting Ability
2:00 pm QPCTL is a Small Molecule Drug Target Modulating the Innate Immune Response
Synopsis
- Identification of QPCTL as a new target that impacts CD47 and several chemokines
- Preclinical evaluation of QPCTL inhibition
2:30 pm Allocetra: Off-The-Shelf, Universal, Macrophage Reprogramming Cell Therapy for Life-Threatening Diseases
Synopsis
- Product description and mechanism of action
- Preclinical and clinical efficacy results – inflammatory indications
- Preclinical efficacy results in solid tumor models
Driving Clinical Operations to Obtain Smooth Development and Validation
2:00 pm Round Table: Crossing the Bridge into the Clinic: Formulating a Strategic Clinical Plan
Synopsis
- Formulating a clinical hypothesis to drive research and secure funding
- Mitigating risk in the clinic to ensure efficiency and smooth clinical development
- Safeguarding patient access to maintain patient supply and guarantee study enrolment
2:30 pm Exploring Mechanisms Underlying Macrophage-Directed Therapy Resistance in Acute Myeloid Leukaemia
Synopsis
- Examining the reasons behind therapy resistance to identify methods to reverse it
- Understanding the influence of the tumor microenvironment on resistance to
- Overcoming resistance to broaden and prolong therapy response in patients
3:00 pm
Afternoon Refreshments and Networking
Exploring Macrophage Applications Beyond Oncology to Uncover Future Indications with Targeting Potential
3:30 pm Treating Lysosomal Storage Diseases Using iPSC-derived Microglia
Synopsis
Virtual Presentation
- Inherited, lysosomal storage diseases (LSDs) are characterized by the pathologic build-up of toxic material in the body’s cells because of a genetic defect resulting in enzyme deficiencies.
- Microglia, the resident myeloid cells of the brain, are dispersed throughout the brain and microglia progenitors can readily be derived from human induced pluripotent stem cells (hiPSCs); BlueRock identified them as a potential cell therapy for LSDs
- We show that wildtype donor microglia progenitors can cross-correct the enzymatic deficiency in several LSDs in vitro and in vivo by transferring the missing enzyme to diseased cells
4:00 pm Targeting the Oxidized Macrophage Migration Inhibitory Factor (oxMIF) in Inflammation and its Link to Oncology
Synopsis
- oxMIF is the disease-related and druggable isoform of the macrophage migration inhibitory factor
- ON104 is an optimized antibody targeting oxMIF for the treatment of patients with inflammatory conditions
- oxMIF provides a critical link between inflammation and immuno-oncology